TD Cowen cuts Orthofix Medical stock price target on supply issues
TD Cowen reduced its price target for Orthofix Medical (OFIX) to $9 from $12, citing Q3 results that missed expectations and supply issues. The stock has fallen 48% year-to-date. OFIX revised its 2026 guidance lower due to Q4 challenges. Despite a Q3 earnings beat, revenue missed forecasts, leading to a negative market reaction. Analysts expect profitability in 2024 with earnings of $0.69 per share.
How this was made
The 30-second read
Why it matters
Analyst target reduction may accelerate the stock's recent 10% weekly decline, but fair‑value estimates imply upside potential if issues resolve.
Market read
The target cut provides fresh actionable insight for traders holding or considering OFIX.
What to watch
Potential profitability this year and a possible rebound if supply constraints ease.
Background
Orthofix Medical reported Q3 miss and supply constraints in its spine product line, prompting a guidance downgrade for FY 2026.
Ticker impact
TD Cowen lowered its price target on Orthofix Medical to $9 from $12 following Q3 results and revised FY guidance.
likely downside as the market prices in the lower target and guidance revision
The new $9 target is substantially below the prior $12 and below current trading price, indicating potential further sell pressure.
Market effects
Spine medical device sector may face broader scrutiny as supply issues are noted as not unique to Orthofix.
US small‑cap healthcare segment could see modest pullback.
Limited; impact confined to niche medical device investors.
Counterpoint
Fair value models still show a $12.30 valuation, suggesting the price target cut may be overly pessimistic.
Key entities
- analystTD Cowen
Equity research firm that cut the price target.
- companyOrthofix Medical
Medical device maker focused on spine products.


